GTHP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GTHP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Guided Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was $-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.03.
Guided Therapeutics's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.03.
Guided Therapeutics's EPS without NRI for the three months ended in Sep. 2024 was $-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -0.03.
During the past 3 years, the average EPS without NRI Growth Rate was 26.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 7.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 89.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Guided Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 99.80% per year. The lowest was -68.80% per year. And the median was 64.75% per year.
The historical data trend for Guided Therapeutics's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guided Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EPS (Basic) | Get a 7-Day Free Trial |
![]() |
![]() |
-0.58 | -0.04 | -0.18 | -0.15 | -0.07 |
Guided Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EPS (Basic) | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-0.01 | - | -0.01 | -0.01 | -0.01 |
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Guided Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as
Basic EPS (A: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-3.489 | - | 0.171) | / | 51.131 | |
= | -0.07 |
Guided Therapeutics's Basic EPS for the quarter that ended in Sep. 2024 is calculated as
Basic EPS (Q: Sep. 2024 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-0.654 | - | 0.038) | / | 57.039 | |
= | -0.01 |
EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guided Therapeutics (OTCPK:GTHP) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Guided Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
John E Imhoff | director, 10 percent owner | P.O. BOX 31083, SEA ISLAND GA 31561 |
Alan Grujic | director | 349 FORBES AVE, SAN RAFAEL CA 94901 |
Michael C James | director | 2040 MAIN STREET, SUITE 225, IRVINE CA 92614 |
Richard P. Blumberg | director | 2357 HOBART AVENUE S.W., SEATTLE WA 98116 |
Lynne H Imhoff | 10 percent owner | 2716 SOUTH ROCKFORD ROAD, TULSA OK 74114 |
Gene S Cartwright | officer: Chief Executive Officer | 4088 COMMERCIAL AVE, NORTHBROOK IL 60062 |
Parsons & Whittemore Enterprises Corp. | 10 percent owner | 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573 |
George F. Landegger 2010 10-year Grat | 10 percent owner | 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573 |
George F Landegger | 10 percent owner | 4 INTERNATIONAL DRIVE, RYE BROOK, NEW YORK NY 10573 |
Whittemore Collection Ltd | 10 percent owner | 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573 |
George F. Landegger 2010 5-year Grat | 10 percent owner | 4 INTERNATIONAL DRIVE, RYE BROOK NY 10573 |
Linda Rosenstock | director | 5995 PLAZA DRIVE, MAIL STOP CY20-103, CYPRESS CA 90630 |
Jonathan M Niloff | director | C/O MATRITECH, INC., 330 NEVADA STREET, NEWTON MA 02460 |
Ronald W Allen | director | P O BOX 1734, ATLANTA GA 30301 |
Shabbir Bakir Bambot | officer: VP of R & D | 4955 AVALON RIDGE PARKWAY, SUITE 300, NORCROSS GA 30071 |
From GuruFocus
By Marketwired Marketwired • 05-16-2018
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.